Is Mirtazapine an Antihistamine or Antidepressant?

Mirtazapine is officially classified as an antidepressant, but it owes many of its most noticeable effects to powerful antihistamine activity at the H1 receptor. In pharmacological terms, it is both: a drug designed and approved to treat depression whose receptor profile overlaps heavily with that of a first-generation antihistamine. This dual identity explains why mirtazapine makes people drowsy, stimulates appetite, and sometimes gets prescribed for conditions that have nothing to do with mood.

What Mirtazapine Actually Does at the Receptor Level

Mirtazapine belongs to a class called noradrenergic and specific serotonergic antidepressants, sometimes abbreviated NaSSA. It works by blocking a set of receptors that normally act as brakes on the release of norepinephrine and serotonin in the brain. Specifically, it blocks alpha-2 adrenergic autoreceptors and heteroreceptors, which increases the release of both norepinephrine and serotonin into the synaptic space.¹ That is the antidepressant part. But mirtazapine also binds strongly to histamine H1 receptors, serotonin 5-HT2 receptors, and serotonin 5-HT3 receptors, while having low affinity for dopamine and muscarinic cholinergic receptors.²

The H1 receptor affinity is not a minor footnote. Mirtazapine’s binding at H1 is strong enough that it produces sedation and appetite stimulation comparable to what you’d expect from a dedicated antihistamine. One pharmacology guide notes that mirtazapine has potent antihistaminic but low anticholinergic properties, meaning its sedation comes from histamine blockade rather than from the anticholinergic pathway responsible for the dry mouth and blurry vision seen with older sedating drugs.³ So while a first-generation antihistamine like diphenhydramine blocks H1 receptors and makes you sleepy as a side effect, mirtazapine blocks H1 receptors and makes you sleepy as one of several simultaneous pharmacological actions. The drowsiness feels similar because the mechanism is similar.

Why It Makes You Sleepy and Hungry

The two side effects that define the mirtazapine experience for most people are sedation and weight gain, and both trace directly back to its antihistamine activity. Histamine normally promotes wakefulness, so blocking it has a strong sedating effect. A placebo-controlled study in healthy volunteers found that mirtazapine significantly increased slow-wave (deep) sleep while reducing the lighter stage-1 sleep that characterizes a restless night.⁴ This is why clinicians often recommend taking it at bedtime: the sedation is strongest in the first few hours and, for many people, eases off by morning.

The appetite and weight effects are a combination of H1 blockade and 5-HT2C receptor blockade. Both receptors normally play a role in suppressing hunger, so blocking them tips the balance toward eating more. In practice, mirtazapine has been linked to an average weight gain of about 1.7 kilograms in the first 12 weeks of treatment.⁵ That number is an average; some people gain considerably more, and others notice little change. It is enough, though, that clinicians sometimes deliberately choose mirtazapine for patients who are underweight or have lost their appetite due to illness or another medication.

How It Stacks Up as an Antidepressant

Because the sedation and appetite effects are so noticeable, people sometimes wonder whether mirtazapine is really pulling its weight as an antidepressant or just making them sleep and eat. The clinical trial data say it genuinely treats depression, and it may even kick in somewhat faster than SSRIs. A Cochrane systematic review that pooled 12 trials comparing mirtazapine to SSRIs found mirtazapine was significantly more effective at two weeks and still modestly more effective at the end of the treatment period. Against venlafaxine (an SNRI), the advantage at two weeks was even larger.⁶ A retrospective analysis across three clinical trials also found that about 13 percent of mirtazapine patients showed persistent improvement in the first week, compared with 6 percent on SSRIs, though the authors cautioned this was a preliminary signal given the study design.⁷

The antidepressant effect comes from the alpha-2 receptor blockade and the downstream increase in norepinephrine and serotonin signaling, not from the antihistamine activity. Animal studies have confirmed that mirtazapine enhances serotonergic transmission in the brain by blocking alpha-2 adrenergic auto- and heteroreceptors on serotonin neurons.⁸ So the mood-lifting mechanism is pharmacologically distinct from the sedation and appetite mechanisms, even though they all happen simultaneously in the same pill.

Off-Label Use for Insomnia

Given its sedating profile, mirtazapine frequently gets prescribed off-label at low doses for insomnia, even when the patient does not have depression. The evidence here has gotten stronger in recent years. A randomized, double-blind trial in general practice (the DREAMING study) found that low-dose mirtazapine produced a large improvement in insomnia severity scores compared to placebo at six weeks, with about half of the mirtazapine group reporting clinically meaningful improvement or recovery.⁹ A separate crossover trial found that a low dose of mirtazapine increased total sleep time by about half an hour and cut the number of nighttime awakenings by roughly 35 to 40 percent under stressful conditions, while specifically boosting deep sleep.¹⁰

In older adults, a population especially vulnerable to insomnia, a randomized placebo-controlled trial (the MIRAGE study) showed that mirtazapine significantly reduced insomnia severity after 28 days.¹¹ The appeal for this age group is that mirtazapine lacks the anticholinergic burden that makes many older sedating drugs risky for seniors. Drugs with strong anticholinergic effects can worsen confusion and increase fall risk, and mirtazapine largely sidesteps that problem.

Nausea, Itch, and Cancer Cachexia

Mirtazapine’s receptor profile creates a grab bag of potential off-label uses. Its blockade of 5-HT3 receptors, the same target hit by ondansetron (Zofran), gives it anti-nausea properties. One review noted that mirtazapine appears to be roughly as effective as olanzapine in reducing chemotherapy-induced nausea and vomiting, though evidence for improving anorexia in advanced cancer is limited.¹² The 5-HT3 blockade, along with its anti-nausea reputation, has led to its use in palliative care settings.¹³

For cancer-related appetite loss and wasting (cachexia), the results are less encouraging than the pharmacology might suggest. A double-blind, placebo-controlled trial in 120 patients with incurable solid tumors found that mirtazapine 15 mg at bedtime was no better than placebo at improving appetite after 28 days.¹⁴ Another trial comparing mirtazapine to megestrol (a hormonal agent commonly used for cachexia) found megestrol had a significantly greater effect on appetite at eight weeks, though women in the mirtazapine group did gain meaningful weight.¹⁵ So while the antihistamine-driven appetite boost is real in general psychiatric populations, it does not always translate into benefit for patients dealing with the complex metabolic disruption of advanced cancer.

The H1 blockade also explains a less well-known use: managing chronic itch. A pilot study of patients with inflammatory skin diseases and severe nighttime itching found that mirtazapine reduced pruritus, likely through the combination of H1 antagonism and sedation that helps patients sleep through the itch.¹⁶ This was a small, uncontrolled study, so the evidence is preliminary, but the rationale is pharmacologically sound.

Side Effects and Safety Concerns

The most common side effects are exactly what you’d predict from the receptor profile: drowsiness and weight gain. A large prescription-event monitoring study of over 13,500 patients in England found that drowsiness and sedation were the most frequently reported adverse reactions, with the highest incidence in the first month of treatment. Malaise and fatigue were the second most common.¹⁷ Most people find the sedation fades somewhat after the first couple of weeks as the body adjusts, though it can persist at higher doses.

A rarer but more serious concern is agranulocytosis, a dangerous drop in white blood cell counts. This is uncommon enough that the same monitoring study reported only two cases of bone marrow toxicity and one of myelodysplasia among those 13,500-plus patients.¹⁷ Case reports continue to surface, however, and the risk is enough that prescribers are advised to monitor for unexplained fever, sore throat, or other signs of infection during early treatment.¹⁸

One dose-related question that comes up often is whether higher doses cause more agitation or cardiovascular effects. A study that explored the relationship between mirtazapine dose and adrenergic side effects found no clear link between dose and the incidence of abnormal dreams, agitation, anxiety, insomnia, or hypertension. There was a possible association with tachycardia, but the finding did not hold up after correcting for multiple comparisons.¹⁹ Paradoxically, many clinicians observe that mirtazapine is more sedating at lower doses (like 7.5 or 15 mg) than at higher ones (30 or 45 mg), because higher doses bring more noradrenergic activity that counteracts some of the histamine-driven drowsiness.

How Your Body Processes It

Mirtazapine is broken down primarily by liver enzymes, especially CYP2D6 and CYP3A4/3A5, with CYP1A2 playing a smaller role. Research in Japanese patients showed that people who are poor metabolizers through the CYP2D6 pathway ended up with significantly higher blood levels of the drug at the same dose, because their bodies cleared it more slowly.²⁰ This matters because drugs that inhibit CYP2D6 or CYP3A (like some antifungals, certain other psychiatric medications, and even grapefruit juice for CYP3A) can effectively raise mirtazapine levels and intensify its effects. If you’re on mirtazapine and a new medication is added, it’s worth asking your pharmacist about interactions through these pathways.

Stopping Mirtazapine

Withdrawal symptoms can occur when mirtazapine is stopped abruptly, and the antihistamine activity plays a role here too. The most commonly reported symptoms include dizziness, nausea, anxiety, insomnia, irritability, and restlessness.²¹ Less intuitively, some people develop intense itching after stopping. One case report hypothesized that this withdrawal-related pruritus stems from a rebound effect: the brain’s histamine receptors have been chronically blocked, and when the drug is suddenly removed, the system overreacts as histamine signaling floods back in.²¹ This is essentially the same phenomenon you’d see after stopping a long course of any antihistamine: receptor upregulation leading to a temporary rebound. It reinforces the point that mirtazapine’s antihistamine properties are not incidental; they are pharmacologically significant enough to produce their own withdrawal effects.

Mirtazapine in Pregnancy and Breastfeeding

For people who become pregnant while taking mirtazapine, the available data are generally reassuring but incomplete. Two systematic reviews have examined the question. The earlier one, covering 390 exposed neonates across 31 papers, found no increased risk of major congenital malformations and described overall safety as acceptable, though there was a possible association with spontaneous abortion that could also be explained by the underlying psychiatric illness rather than the drug itself.²² A more recent review confirmed the broadly reassuring picture but flagged neonatal adaptation syndrome (temporary breathing and feeding difficulties in the newborn) as a concern after exposure in the last trimester, and noted that evidence quality remains low overall.²³ Data on breastfeeding are too scarce for firm conclusions, though the limited reports suggest low transfer to breast milk.

The Classification Debate

Even among pharmacologists, there has been some back-and-forth about how to label mirtazapine. It was originally classed under the NaSSA designation, but a historical analysis has pointed out that the evidence for its serotonergic mechanism was disputed and the label may oversimplify what the drug actually does. Some researchers have argued it should be described more precisely as a norepinephrine release stimulator and alpha-2/5-HT2 receptor blocker, with the serotonin-boosting claim treated as less certain.²⁴ None of this changes how the drug works in practice, but it does illustrate why people get confused about what mirtazapine “is.” Its mechanism does not fit neatly into the SSRI or tricyclic categories most people have heard of, and the official label glosses over the fact that a big chunk of what patients actually feel comes from the antihistamine receptor blockade.

Mirtazapine for Cats

One of the odder chapters in mirtazapine’s story is its popularity in veterinary medicine, specifically for cats. Cats with chronic kidney disease often stop eating and lose dangerous amounts of weight, and mirtazapine’s appetite-stimulating and anti-nausea properties make it a useful tool in that setting. A placebo-controlled crossover trial in cats with kidney disease found that mirtazapine significantly increased appetite and activity, reduced vomiting, and produced a median weight gain of about 0.18 kilograms during the treatment period.²⁵ A transdermal ointment (applied to the ear) was developed to make dosing easier, and studies have confirmed it also increases appetite and body weight in cats, despite some inconsistencies in compounding quality.²⁶ A survey of cat owners found the medication was generally well received.²⁷ It is one of the clearest examples of mirtazapine’s antihistamine-related effects being the primary reason for prescribing it, since no one is treating a cat for depression. The drug is chosen entirely for what the H1 and 5-HT3 blockade can do for appetite and nausea.